Ambalal Sarabhai Enterprises Ltd
AMBALALSAAmbalal Sarabhai Enterprises Ltd
AMBALALSA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.17 | 3.28 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ambalal Sarabhai Enterprises Limited is a manufacturer of formulations. It markets specialty pharmaceutical products under its three sub-divisions: oncology, infertility and uro-gynaec.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 226.99 | 140.37 | 150.24 | 159.60 | 157.89 | 203.33 | 245.19 | 182.77 | 183.94 | 189.73 | ||||||||||
Raw Materials | 71.25 | 77.06 | 71.33 | 90.28 | 81.51 | 98.39 | 114.07 | 105.24 | 98.61 | 169.49 | ||||||||||
| Power & Fuel Cost | 3.67 | 2.68 | 2.84 | 3.22 | 2.71 | 2.86 | 3.64 | 4.20 | 5.48 | |||||||||||
| Employee Cost | 31.29 | 28.71 | 26.67 | 26.02 | 27.06 | 28.17 | 25.27 | 22.05 | 24.59 | |||||||||||
| Selling & Administrative Expenses | 19.88 | 18.98 | 18.35 | 18.34 | 17.15 | 19.14 | 16.67 | 19.62 | 20.70 | |||||||||||
| Operating & Other expenses | 18.58 | 17.52 | 17.56 | 8.13 | 8.35 | 16.63 | 26.98 | 11.02 | 18.24 | |||||||||||
EBITDA | 82.32 | -4.58 | 13.49 | 13.61 | 21.11 | 38.14 | 58.56 | 20.64 | 16.32 | 20.24 | ||||||||||
| Depreciation/Amortization | 16.54 | 4.27 | 2.12 | 2.10 | 2.57 | 2.41 | 2.32 | 2.76 | 3.57 | 3.50 | ||||||||||
| PBIT | 65.78 | -8.85 | 11.37 | 11.51 | 18.54 | 35.73 | 56.24 | 17.88 | 12.75 | 16.74 | ||||||||||
| Interest & Other Items | 4.10 | 4.77 | 3.41 | 3.29 | 3.61 | 3.20 | 2.04 | 2.71 | 6.09 | 3.76 | ||||||||||
| PBT | 61.68 | -13.62 | 7.96 | 8.22 | 14.93 | 32.53 | 54.20 | 15.17 | 6.66 | 12.98 | ||||||||||
| Taxes & Other Items | 13.54 | 4.60 | 6.69 | 3.97 | 0.88 | 3.18 | 6.98 | 3.72 | 0.98 | 1.20 | ||||||||||
| Net Income | 48.14 | -18.22 | 1.27 | 4.25 | 14.05 | 29.35 | 47.22 | 11.45 | 5.68 | 11.78 | ||||||||||
| EPS | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.49 | 0.74 | 1.54 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Ambalal Sarabhai Enterprises Ltd | 79.16 | 3.28 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare AMBALALSA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.68%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
AMBALALSA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAmbalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Net profit of Ambalal Sarabhai Enterprises reported to Rs 0.35 crore in the quarter ended June 2024 as against net loss of Rs 4.87 crore during the previous quarter ended June 2023. Sales rose 12.74% to Rs 40.70 crore in the quarter ended June 2024 as against Rs 36.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales40.7036.10 13 OPM %1.18-11.00 - PBDT1.82-3.55 LP PBT0.84-4.60 LP NP0.35-4.87 LP Powered by Capital Market - Live
Ambalal Sarabhai Enterprises will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Cosara Diagnostics gets CDSCO license to manufacture SARAGENE Dengue Test Kit
Ambalal Sarabhai Enterprises consolidated net profit rises 2760.22% in the June 2021 quarter
Ambalal Sarabhai Enterprises consolidated net profit rises 20.84% in the March 2021 quarter
Ambalal Sarabhai Enterprises reports standalone net loss of Rs 8.93 crore in the March 2021 quarter
Ambalal Sarabhai spurts after unit hikes production of Amphotericin B
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2.88%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.07% to 0.05%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 5.97%, vs industry avg of 15.28%